BPM’s DNlite-IVD103 Granted Regulatory Approval in Thailand, Marking Its Third Global Market Entry

Bio Preventive Medicine Corp. ("BPM") announced today that its proprietary diagnostic test, DNlite-IVD103 (Application Name: DNlite-DKD uPTM-FetA ELISA Kits), has officially received IVD marketing authorization from the Thai regulatory authority. Following the European Union and Malaysia, Thailand becomes the third region to approve the product for commercial sale.

Precision Risk Assessment for Type 2 Diabetes

DNlite-IVD103 is specifically designed for the risk assessment and prediction of renal function deterioration in patients with Type 2 diabetes. This approved iteration is a newly improved version of the DKD diagnostic kit, featuring optimized operating times and enhanced storage and transportation conditions.

Enhanced Competitiveness through Logistics Optimization 

These technical advancements will significantly reduce logistics and shipping costs, thereby strengthening the product's overall market competitiveness. Moving forward, BPM will work closely with local distribution partners to formulate strategic marketing plans, aiming to drive robust revenue growth and commercial momentum in the Thai market.